It has been assessed in several phase I trials in previously treated advanced NSCLC, either as monotherapy88 or in combination with pemetrexed chemotherapy.89 The combination of everolimus and EGFR inhibitors has also been evaluated in phase II trials in NSCLC patients unselected for EGFR mutation status. This evidence concerns the gene EGFR and non-small cell lung carcinoma.